Drug Profile

MVT 602

Alternative Names: MVT-602; RVT-602; TAK-448

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Millennium
Developer Millennium; Sumitomo Pharma; Sumitomo Pharma America; Takeda; Takeda Oncology
Class Infertility therapies; Oligopeptides
Mechanism of Action KISS1R protein agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Female infertility; Hypogonadism
Discontinued Prostate cancer

Most Recent Events

10 Mar 2023 Myovant Sciences has been acquired by Sumitovant Biopharma
29 Nov 2022 Phase II development in Female infertility is ongoing Germany and Netherlands (SC) (Myovant Sciences pipeline, November 2022)
01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com